Concept Richtlijn Erfelijke darmkanker 2007 versie 7 - Oncoline

AanbevelingenDe mogelijkheden voor sedatie, pijnbestrijding en darmvoorbereiding dienen voorafgaandaan de colonoscopie te worden besproken met de patiënt (zie richtlijn sedatie buiten het OKcomplex).Om compliance met darmonderzoek te verhogen, is het aan te bevelen herinneringsbrieventoe te sturen met daarin een oproep voor het onderzoek.Literatuur1. Bleiker EMA, Menko FH, Taal BG, Kluijt I Wever LD, Gerritsma MA et al. Screeningbehavior of individuals at high risk for colorectal cancer. Gastroenterology 2005;128:280-7.2. Cibula DA, Morrow CB. Determining local colorectal cancer screening utilization patterns.J Public Health Manag Pract 2003;9:315-21.3. Friedman LC, Webb JA, Richards CS, Plon SE. Psychological and behavioral factorsassociated with colorectal cancer screening among Ashkenazim. Prev Med 1999;29:119-254. Hadley DW, Jenkins JF, Dimond E, De Carvalho M, Kirsch I, Palmer CG. Colon cancerscreening practices after genetic counseling and testing for hereditary nonpolyposiscolorectal cancer. J Clin Oncol 2004;22;39-44.5. Halbert CH, Lynch H, Lynch J, Main D, Kucharski S, Rustgi AK et al. Colon cancerscreening practices following genetic testing for hereditary nonpolyposis colon cancer(HNPCC) mutations. Arch Intern Med 2004;164:1881-7.6. Harris MA, Byles JE. A survey of screening compliance among first degree relatives ofpeople with colon cancer in new south wales. J Med Screen 1997;4:29-34.7. Holt WS Jr. Factors affecting compliance with screening sigmoidoscopy. J Fam Pract.1991;32:585-9.8. Houlston RS, Murday V, Harocopos C, Williams CB, Slack J. Screening and geneticcounselling for relatives of patients with colorectal cancer in a family cancer clinic. BMJ.1990;301:366-8.9. James AS, Campbell MK, Hudson MA. Perceived barriers and benefits to colon cancerscreening among African Americans in North Carolina: how does perception relate toscreening behavior? Cancer Epidemiol Biomarkers Prev 2002;11:529-34.10. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P et al.Controlled 15-year trial on screening for colorectal cancer in families with hereditarynonpolyposis colorectal cancer. Gastroenterology 2000:118:829-34.11. Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in familieswith hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-11.12. Jass JR et al. Screening for hereditary non-polyposis colorectal cancer in New Zealand.Eur J Gastroenterol Hepatol 1992;4:523-27.13. Kinney AY, Choi YA, De Vellis B, Kobetz E, Millikan RC, Sandler RS. Interest in genetictesting among first-degree relatives of colorectal cancer patients. Am J Prev Med2000;18:249-52.14. Lewis SF, Jensen NM. Screening sigmoidoscopy. Factors associated with utilization. JGen Intern Med 1996:11:542-4.15. Lynch HT, Smyrk TC, Lanspa SJ, Jenkins JX, Cavalieri J, Lynch JF. Cancer controlproblems in the lynch syndromes. Dis Colon Rectum 1993;36:254-60.Concept landelijke richtlijn erfelijke darmkanker versie 7 d.d. 7 november 2007.72